<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813969</url>
  </required_header>
  <id_info>
    <org_study_id>MS-MSC-001</org_study_id>
    <nct_id>NCT00813969</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS</brief_title>
  <official_title>A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal&#xD;
      stem cell transplantation, involving approximately 24 ambulatory participants with relapsing&#xD;
      forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/&#xD;
      progressive relapsing MS) and evidence of involvement of the anterior afferent visual system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability of autologous MSC transplantation over 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <condition>Progressive Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Autologous MSC transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal stem cell transplantation</intervention_name>
    <description>A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion</description>
    <arm_group_label>Autologous MSC transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 55, inclusive.&#xD;
&#xD;
          -  Diagnosis of MS&#xD;
&#xD;
          -  Relapsing form of MS (relapsing-remitting, secondary progressive, or&#xD;
             progressive-relapsing course).&#xD;
&#xD;
          -  EDSS score 3.0-6.5, inclusive. (Must be able to walk)&#xD;
&#xD;
          -  Active disease during prior 24 months.&#xD;
&#xD;
          -  Documented evidence of involvement of the anterior afferent visual system: previous&#xD;
             optic neuritis, optic atrophy or an afferent pupillary defect on exam, RNFL thickness&#xD;
             on OCT &lt;LLN in at least one eye OR documented VEP latency in at least 1 eye.&#xD;
&#xD;
          -  Cranial MRI scan demonstrating T2-hyperintense lesions satisfying diagnostic criteria&#xD;
             for MS&#xD;
&#xD;
          -  Ability to perform the component tests of the MSFC (T25FW, 9HPT, PASAT3).&#xD;
&#xD;
          -  Ability to perform SLCLA.&#xD;
&#xD;
          -  Has given written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia,&#xD;
             septicemia) within 30 days of the Screening Visit.&#xD;
&#xD;
          -  History of cancer other than basal cell carcinoma of the skin.&#xD;
&#xD;
          -  History or laboratory results indicative of any significant cardiac, endocrine,&#xD;
             hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary,&#xD;
             gastrointestinal, dermatologic, psychiatric, renal, neoplastic, or other disorder that&#xD;
             in the opinion of the Principal Investigator would preclude the safe performance of BM&#xD;
             aspiration, infusion of autologous MSCs, or performance of any of the planned study&#xD;
             assessments.&#xD;
&#xD;
          -  Abnormal blood tests which exceed designated limits.&#xD;
&#xD;
          -  Positive screening tests for hepatitis B, hepatitis C, HIV 1&amp;2, HTLV I/II, CMV, West&#xD;
             Nile virus, syphilis, blood parasite infection.&#xD;
&#xD;
          -  Clinically significant abnormality on chest X-ray.&#xD;
&#xD;
          -  Clinically significant abnormality on EKG.&#xD;
&#xD;
          -  Oxygen-saturation &lt;90% on room air.&#xD;
&#xD;
          -  History of alcohol or drug abuse within one year.&#xD;
&#xD;
          -  Any metallic material or electronic device in the body, or condition that precludes&#xD;
             the participant from undergoing MRI with Gd administration.&#xD;
&#xD;
          -  Uncontrolled glaucoma or other ocular condition that precludes performing OCT or&#xD;
             interpreting the results.&#xD;
&#xD;
          -  MS relapse with onset within 30 days prior to the Screening Visit or the participant&#xD;
             has not stabilized from a previous relapse at the time of the Screening Visit.&#xD;
&#xD;
          -  Current treatment with an investigational MS disease therapy.&#xD;
&#xD;
          -  Prior treatment with:&#xD;
&#xD;
        Total lymphoid irradiation. Cladribine. T-cell or T-cell receptor vaccination. Campath-1h&#xD;
        (alemtuzumab). Rituxan (rituximab).&#xD;
&#xD;
          -  Prior treatment within three months with:&#xD;
&#xD;
        Tysabri (natalizumab). Gilenya (Fingolimod/FTY720). Zenapax (daclizumab). Cytoxan&#xD;
        (cyclophosphamide). Novantrone (mitoxantrone). Cyclosporine. CellCept (mycophenolate&#xD;
        mofetil). Imuran (azathioprine). Rheumatrex (methotrexate). IV gamma globulin. Plasma&#xD;
        exchange.&#xD;
&#xD;
          -  Prior treatment within one month:&#xD;
&#xD;
        Systemic corticosteroids with daily dose equivalent to Prednisone 60 mg or greater.&#xD;
&#xD;
          -  Female participants who are not post-menopausal for at least one year, not surgically&#xD;
             sterile, or not willing to practice effective contraception.&#xD;
&#xD;
          -  Nursing mothers, pregnant women, or women planning to become pregnant during the&#xD;
             study.&#xD;
&#xD;
          -  Male participants who are not willing to practice effective contraception.&#xD;
&#xD;
          -  Unwillingness or inability to comply with the requirements of this protocol including&#xD;
             the presence of any condition (physical, mental, or social) that, in the opinion of&#xD;
             the Principal Investigator, is likely to affect the participant's ability to comply&#xD;
             with the study protocol.&#xD;
&#xD;
          -  Any other reason that, in the opinion of the Principal Investigator, makes the&#xD;
             participant unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Cohen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Mellen Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal Stem Cell</keyword>
  <keyword>MSC</keyword>
  <keyword>Autologous</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

